Association between plasma Se and renal outcomes
decline in renal function, CKD, chronic kidney disease, hypertensive
During the median treatment duration of 4.4 years (IQR: 4.2–4.6 years), a rapid decline in renal function and the development or progression of CKD occurred in 72 (7.7%) and 33 (3.5%) participants, respectively.As shown in The frequency distribution of baseline plasma selenium in 935 participants by outcome status: (A) rapid decline in renal function and (B) development or progression of CKD. CKD, chronic kidney disease.Similar results were found for the association of plasma Se and the risk of the development or progression of CKD (The association between plasma selenium and renal outcomes in hypertensive adults from a folate supplementation trialCKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Adjusted for age, sex, eGFR, treatment group, BMI, 